Skip to content
Screener

Income Tax at other companies

Amgen logo
AmgenAMGN
$393M+189%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$230.9M+81.7%
Gilead Sciences logo
Gilead SciencesGILD
$242M-48.3%
Biohaven logo
BiohavenBHVN
$272K-55.3%
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
$5.51M-29.9%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
$60K-4.8%

Other financials

Income statement

See full
Revenue$238.9M+19,583%
Gross profit$238.9M+19,763%
Operating income$73.5M+162%
Net income$80.1M+172%
EPS (diluted)$0.47+159%

Balance sheet

See full
Cash & equivalents$287.6M-6.1%
Total debt$93.3M-8.8%
Total equity$982.5M+3.7%
Total assets$1.2B+1.9%

Cash flow

See full
Operating cash flow-$132.4M-69.5%
CapEx$32.0K-98.7%
Free cash flow-$132.8M-66.5%

Valuation

See full
Market cap$1.48B+111%
Enterprise value$1.29B+159%
P/S4.9×-32.1×

Profitability

See full
Gross margin96.1%-2.7pp
Operating margin-92.4%-45.5pp
Net margin-83%-40.9pp
FCF margin-686.5%-273pp

Returns & leverage

See full
Return on equity-26.1%-7.9pp
Debt / equity0.1×0.0×
Current ratio-1.0×

Where this comes from

Reported directly by Vir Biotechnology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.

The source filing: Vir Biotechnology, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:20 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053549
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Other (expense) income, net(451)226(705)154
Total other income6,7927,62913,55726,227
Income (loss) before provision for income taxes80,259(110,788)(45,266)(231,737)
Provision for income taxes(179)(170)(349)(186)
Net income (loss)$80,080$(110,958)$(45,615)$(231,923)
Net income (loss) per share, basic$0.48$(0.80)$(0.29)$(1.68)
Net income (loss) per share, diluted$0.47$(0.80)$(0.29)$(1.68)
Weighted-average shares outstanding, basic167,719,015138,447,469157,613,578137,960,888

Item 1. Financial Statements (unaudited)

FAQ

What is Vir Biotechnology, Inc.'s income tax?
Vir Biotechnology, Inc. (VIR) reported income tax of $179K in Q2 2026.
How has Vir Biotechnology, Inc.'s income tax changed year-over-year?
Vir Biotechnology, Inc.'s income tax increased by 5.3% year-over-year, from $170K to $179K.
What is the long-term trend for Vir Biotechnology, Inc.'s income tax?
Over 2 years (2021 to 2024), Vir Biotechnology, Inc.'s income tax has grown at a -76.8% compound annual growth rate (CAGR), from $21.22M to -$1.15M.
What does income tax mean?
Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.

Ask your AI about Vir Biotechnology, Inc.'s income tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude